Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02807454 · OUTCOME

Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma · Source last updated 2023-02-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
80% Confidence Interval
Time frame
From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)

What was measured

Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

Analysis population: All participants who received at least 1 dose of the study medications. Pre-specified for data to be collected only in the PD3 arm.

Groups in this outcome

PD3 Arm

Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
PD3 Arm5

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
PD3 Arm9.02Not reported6.918.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.9
        upper Limit
        18.5
        value
        9.02
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    units
    Participants
description
Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).
dispersion Type
80% Confidence Interval
groups
  1. description
    Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \> 75 Years Old) administered within a 28-day cycle for a maximum of 22 cycles
    id
    OG000
    title
    PD3 Arm
param Type
MEDIAN
population Description
All participants who received at least 1 dose of the study medications. Pre-specified for data to be collected only in the PD3 arm.
reporting Status
POSTED
time Frame
From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)
title
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice